Anakinra for intravenous immunoglobulin-resistant Kawasaki disease: a systematic literature review. | ClinicLens
Approximately 10%-20% of patients with Kawasaki disease (KD) are resistant to intravenous immunoglobulins (IVIG) and are at increased risk of developing coronary artery aneurysms (CAA). A potential therapeutic role of anakinra (ANK) in refractory KD has been suggested. The aim of
Medical Literature · Updated
← Back to articlesIf the embedded page does not load in your browser, open it directly.